1. Home
  2. RFIL vs ICCC Comparison

RFIL vs ICCC Comparison

Compare RFIL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RF Industries Ltd.

RFIL

RF Industries Ltd.

HOLD

Current Price

$18.12

Market Cap

191.3M

Sector

Technology

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$9.53

Market Cap

75.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFIL
ICCC
Founded
1979
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
191.3M
75.8M
IPO Year
1996
1995

Fundamental Metrics

Financial Performance
Metric
RFIL
ICCC
Price
$18.12
$9.53
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$11.25
N/A
AVG Volume (30 Days)
206.7K
26.7K
Earning Date
06-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
101.59
53.85
EPS
N/A
0.21
Revenue
$55,325,000.00
$26,493,169.00
Revenue This Year
$9.65
N/A
Revenue Next Year
$6.40
N/A
P/E Ratio
$1,203.00
$46.10
Revenue Growth
10.22
51.64
52 Week Low
$4.40
$4.52
52 Week High
$19.77
$10.75

Technical Indicators

Market Signals
Indicator
RFIL
ICCC
Relative Strength Index (RSI) 56.02 54.79
Support Level $6.31 $9.29
Resistance Level $19.39 $10.75
Average True Range (ATR) 1.60 0.46
MACD -0.11 -0.11
Stochastic Oscillator 62.23 27.40

Price Performance

Historical Comparison
RFIL
ICCC

About RFIL RF Industries Ltd.

RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: